FDA-approved recombinant platelet-derived growth factor gel for diabetic foot ulcers.
Healix360 supports access to advanced mobile wound care services for patients throughout our coverage area. Services are delivered by licensed physicians and nurse practitioners experienced in the evaluation and management of chronic and complex wounds. Care is coordinated and provided directly to patients in private residences, assisted living communities, and skilled nursing facilities. Regranex works by delivering recombinant human PDGF directly to the wound bed. PDGF is a key signaling molecule that recruits fibroblasts and other repair cells to the wound, stimulates new blood vessel formation (angiogenesis), and accelerates the production of granulation tissue. By replenishing PDGF that is depleted or degraded in chronic diabetic ulcers, the gel restarts a stalled proliferative phase.
A licensed clinician determines whether this treatment is appropriate after evaluating the wound and the patient's medical history.
Treatment decisions are individualized. Potential contraindications and precautions may include:
Once the clinician confirms the wound meets approved indications, the patient or caregiver is taught to apply a thin, measured ribbon of gel to the wound once daily, covering it with a saline-moistened gauze dressing. The gel is rinsed off with saline 12 hours later and a clean moist dressing is reapplied. The clinician monitors wound progress weekly and reassesses if the wound has not reduced in size by approximately 30% after 10 weeks.
Becaplermin gel was FDA-approved based on randomized controlled trials demonstrating significantly higher complete-closure rates in diabetic neuropathic ulcers when added to good wound-care practices compared with placebo gel and good wound care alone. The FDA-required boxed warning regarding malignancy risk in patients using three or more tubes is reviewed with every patient before therapy begins.
Regranex is FDA-approved for diabetic neuropathic ulcers and has a well-characterized safety profile. The FDA does require a boxed warning regarding increased malignancy mortality observed in patients using three or more tubes; the clinician reviews this risk with every patient before prescribing.
Treatment is typically continued for up to 20 weeks while the wound continues to make measurable progress. If the wound has not reduced in size by approximately 30% by week 10, the clinician reassesses whether continuing therapy is appropriate.
Yes. After the licensed clinician confirms the wound meets approved indications and demonstrates the application technique, the patient or a trained caregiver applies the once-daily gel between clinical visits.
Regranex is only effective on wounds with adequate blood supply. The clinician confirms perfusion (palpable pulses, ABI/TBI when indicated) before initiating therapy because PDGF cannot stimulate granulation in tissue that is severely ischemic.
Regranex is a prescription medication typically covered by Medicare Part D, Medicaid, and many commercial pharmacy plans, often requiring prior authorization. The coordination team supports the prior authorization process before the first prescription is filled.
Call 877-545-1300 or request a provider to begin care. Healix360 serves Southern California and Nevada and accepts Medicare Part B and most major insurance plans.